By combining clinical patient and routine laboratory characteristics, and, for the first time, immunological parameters, we created a compact prediction model based on four parameters: ISS stage, ECOG, MM therapy, and CD8+ TEMRA cells. Here, CD8A is linked to Miyoshi myopathy.